APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
86 Views
HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline
HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...
426 Views
Primer: HK inno.N (195940 KS) - Aug 2026
HK inno.N's growth is overwhelmingly driven by its blockbuster gastroesophageal reflux disease (GERD) drug, K-CAB, which has achieved a...
92 Views
HK Inno.N (195940 KS): Prescription Drugs Drive 4Q25 Result; Maiden US Approval on Card
HK inno.N reports strong 4Q25 results, driven by prescription drug sales. The company has filed NDA for K-CAB in the U.S. and expects to launch...
248 Views
APAC Healthcare Weekly (August 2) – CSPC, Hengrui, Otsuka, Nippon Shinyaku, PharmaEssnetia, Cipla
Hengrui got NMPA approval for long-acting insulin. FDA approves Otsuka’s new CNS drug. Pharmaessentia announced positive topline result from Phase...
136 Views